Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them

被引：28

作者：

Bruix, Jordi ^{[1
]}

Reig, Maria ^{[1
]}

Sangro, Bruno ^{[2
]}

机构：

[1] Univ Barcelona, BCLC Grp, Hosp Clin, Liver Unit,IDIBAPS,CIBEREHD, Barcelona, Spain

[2] Clin Univ Navarra, Liver Unit, IDISNA, CIBEREHD, Pamplona, Spain

来源：

JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 06期

基金：

欧盟第七框架计划;

关键词：

PHASE-III; SORAFENIB; SURVIVAL; THERAPY; GUIDELINES; ERLOTINIB; RESECTION; BRIVANIB; CRITERIA; TRIALS;

D O I：

10.1016/j.jhep.2017.02.032

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1114 / 1117

页数：4

共 33 条

[1] Phase II study of sorafenib in patients with advanced hepatocellular carcinoma [J].

Abou-Alfa, Ghassan K. ;

Schwartz, Lawrence ;

Ricci, Sergio ;

Amadori, Dino ;

Santoro, Armando ;

Figer, Arie ;

De Greve, Jacques ;

Douillard, Jean-Yves ;

Lathia, Chetan ;

Schwartz, Brian ;

Taylor, Ian ;

Moscovici, Marius ;

Saltz, Leonard B. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4293-4300

[2] Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].

Bruix, J ;

Sherman, M ;

Llovet, JM ;

Beaugrand, M ;

Lencioni, R ;

Burroughs, AK ;

Christensen, E ;

Pagliaro, L ;

Colombo, M ;

Rodés, J .

JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430

[3] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[4] Management of Hepatocellular Carcinoma: An Update [J].

Bruix, Jordi ;

Sherman, Morris .

HEPATOLOGY, 2011, 53 (03) :1020-1022

[5] Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Lin, Deng-Yn ;

Park, Joong-Won ;

Kudo, Masatoshi ;

Qin, Shukui ;

Chung, Hyun-Cheol ;

Song, Xiangqun ;

Xu, Jianming ;

Poggi, Guido ;

Omata, Masao ;

Lowenthal, Susan Pitman ;

Lanzalone, Silvana ;

Yang, Liqiang ;

Lechuga, Maria Jose ;

Raymond, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4067-+

[6] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria [J].

Choi, Haesun ;

Charnsangavej, Chuslip ;

Faria, Silvana C. ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Benjamin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1753-1759

[7] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[8]

European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.ejca.2011.12.021, 10.1016/j.jhep.2011.12.001]

[9]

Huang L, 2017, J CLIN ONCOL, V35

[10] Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma [J].

Ishizawa, Takeaki ;

Hasegawa, Kiyoshi ;

Aoki, Taku ;

Takahashi, Michiro ;

Inoue, Yosuke ;

Sano, Keiji ;

Imamura, Hiroshi ;

Sugawara, Yasuhiko ;

Kokudo, Norihiro ;

Makuuchi, Masatoshi .

GASTROENTEROLOGY, 2008, 134 (07) :1908-1916

← 1 2 3 4 →